A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy

We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3(rd) generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Transl Med
Autors principals: Hirakawa, Haruki, Komiya, Kazutoshi, Nakashima, Chiho, Ogusu, Shinske, Nakamura, Tomomi, Tanaka, Masahide, Takahashi, Koichiro, Egashira, Yoshiaki, Kai, Keita, Kimura, Shinya, Sueoka-Aragane, Naoko
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6312808/
https://ncbi.nlm.nih.gov/pubmed/30603652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2018.11.25
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars